{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chiang SF"],"funding":["Chang Gung University"],"pagination":["874054"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4606116"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2015"],"pubmed_abstract":["<h4>Background</h4>The cancer cell secretome has been recognized as a valuable reservoir for identifying novel serum/plasma biomarkers for different cancers, including colorectal cancer (CRC). This study aimed to verify four CRC cell-secreted proteins (tumor-associated calcium signal transducer 2/trophoblast cell surface antigen 2 (TACSTD2/TROP2), tetraspanin-6 (TSPAN6), bone marrow stromal antigen 2 (BST2), and tumor necrosis factor receptor superfamily member 16 (NGFR)) as potential plasma CRC biomarkers.<h4>Methods</h4>The study population comprises 152 CRC patients and 152 controls. Target protein levels in plasma and tissue samples were assessed by ELISA and immunohistochemistry, respectively.<h4>Results</h4>Among the four candidate proteins examined by ELISA in a small sample set, on"],"journal":["Disease markers"],"pubmed_title":["Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study."],"pmcid":["PMC4606116"],"funding_grant_id":["EMRPD1D0621","MOST103-2325-B-182-003","MOST102-2628-B-182-013-MY3"],"pubmed_authors":["Chen JS","Hsieh LL","Yeh CY","Liang Y","Yu JS","Chiang SF","Chiang JM","Hsiao YC","Tang R","Kan CY","Tsai WS","Hsieh PS"],"additional_accession":[]},"is_claimable":false,"name":"Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study.","description":"<h4>Background</h4>The cancer cell secretome has been recognized as a valuable reservoir for identifying novel serum/plasma biomarkers for different cancers, including colorectal cancer (CRC). This study aimed to verify four CRC cell-secreted proteins (tumor-associated calcium signal transducer 2/trophoblast cell surface antigen 2 (TACSTD2/TROP2), tetraspanin-6 (TSPAN6), bone marrow stromal antigen 2 (BST2), and tumor necrosis factor receptor superfamily member 16 (NGFR)) as potential plasma CRC biomarkers.<h4>Methods</h4>The study population comprises 152 CRC patients and 152 controls. Target protein levels in plasma and tissue samples were assessed by ELISA and immunohistochemistry, respectively.<h4>Results</h4>Among the four candidate proteins examined by ELISA in a small sample set, on","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015","modification":"2026-05-03T17:08:58.04Z","creation":"2019-03-27T02:00:05Z"},"accession":"S-EPMC4606116","cross_references":{"pubmed":["26494939"],"doi":["10.1155/2015/874054"]}}